Evidence map›Paper›PMID 38463606›Full record

ArticleDiabetes epidemiology and management

Anxiety, Depression and Quality of Life in Relation to SARS-CoV-2 Antibodies in Individuals Living with Diabetes During the Second Wave of COVID-19.

Lind Alexander, Cao Yang, Hesser Hugo, Hårdstedt Maria, Jansson Stefan, Lernmark Åke, Sundqvist Martin, Tevell Staffan, Tsai Cheng-Ting, Wahlberg Jeanette and 1 more

Open access · goldAbstract read
In one paragraph

Article in Diabetes epidemiology and management. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Lind AlexanderDepartment of Clinical Sciences Malmö, Lund University, Sweden.ORCID 0000-0002-1473-5468
Cao YangClinical Epidemiology and Biostatistics, School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.ORCID 0000-0002-3552-9153
Hesser HugoSchool of Behavioural, Social and Legal Sciences, Center for Health and Medical Psychology, Örebro University, Sweden.ORCID 0000-0002-9736-8228
Hårdstedt MariaSchool of Medical Sciences, Faculty of Medicine and Health, Örebro University, Sweden.ORCID 0000-0002-3671-5046
Jansson StefanSchool of Medical Sciences, University Health Care Research Centre, Örebro University, Örebro, Sweden.ORCID 0000-0001-6864-4679
Lernmark ÅkeDepartment of Clinical Sciences Malmö, Lund University, Sweden.ORCID 0000-0003-1735-0499
Sundqvist MartinSchool of Medical Sciences, Faculty of Medicine and Health, Örebro University, Sweden.
Tevell StaffanSchool of Medical Sciences, Faculty of Medicine and Health, Örebro University, Sweden.ORCID 0000-0002-9213-9274
Tsai Cheng-TingEnable Biosciences Inc., South San Francisco, CA, USA.ORCID 0000-0002-8718-8821
Wahlberg JeanetteSchool of Medical Sciences, Faculty of Medicine and Health, Örebro University, Sweden.ORCID 0000-0003-4061-6830
Jendle JohanSchool of Medical Sciences, Faculty of Medicine and Health, Örebro University, Sweden.ORCID 0000-0003-1025-1682
Örebro University · SELund University · SEUppsala University · SEEnable Biosciences (United States) · USKarlstad Central Hospital · SELinköping University · SE

Funding

An Ultrasensitive, High-Throughput, and Low-Cost Autoimmunity Panel for the Early Diagnosis and Improved Treatment of Type 1 DiabetesR44DK111005 · NIDDK · ENABLE BIOSCIENCES, INC. · PI SEFTEL, DAVID · 2018 to 2025
$4.4M
NIDDK NIH HHS R44 DK111005
6 · The paper itself

Abstract

Aims: The objective was to compare anxiety, depression, and quality of life (QoL) in individuals living with type 1 (T1D) and type 2 (T2D) diabetes with matched controls during the second wave of the COVID-19 pandemic. Methods: Via randomization, individuals living with diabetes T1D (n= 203) and T2D (n=413), were identified during February-July 2021 through health-care registers. Population controls (n=282) were matched for age, gender, and residential area. Questionnaires included self-assessment of anxiety, depression, QoL, and demographics in relation to SARS-CoV-2 exposure.Blood was collected through home-capillary sampling, and SARS-CoV-2 Nucleocapsid (NCP) and Spike antibodies (SC2_S1) were determined by multiplex Antibody Detection by Agglutination-PCR (ADAP) assays. Results: Younger age and health issues were related to anxiety, depression, and QoL, with no differences between the study groups. Female gender was associated with anxiety, while obesity was associated with lower QoL.The SARS-CoV-2 NCP seroprevalence was higher in T1D (8.9%) compared to T2D (3.9%) and controls (4.0%), while the SARS-CoV-2 SC2_S1 seroprevalence was higher for controls (25.5%) compared to T1D (16.8%) and T2D (14.0%). Conclusions: A higher SARS-CoV-2 infection rate in T1D may be explained by younger age and higher employment rate, and the associated increased risk for viral exposure.

Indexed as

anxietyCOVID-19depressionDiabetesquality of lifeSARS-CoV-2virus antibodies

Identifiers

PMID38463606
PMCPMC10923605
OpenAlexW4389762039

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.